Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
Molecular Cancer Therapeutics|March 13, 2015
The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responsesLisa Christiansson, Stina Söderlund, Sara Mangsbo, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2007
Murine models of acute neuronopathic Gaucher diseaseIda Berglin Enquist, Christophe Lo Bianco, Andreas Ooka, et al.
Mycoses|March 27, 2018
Prospective evaluation of a combination of fungal biomarkers for the diagnosis of invasive fungal disease in high-risk haematology patientsHelena Hammarström, Anna Stjärne Aspelund, Bertil Christensson, et al.
Calcified Tissue International|May 20, 2014
A comparison of osteoclast-rich and osteoclast-poor osteopetrosis in adult mice sheds light on the role of the osteoclast in coupling bone resorption and bone formationChristian S Thudium, Ilana Moscatelli, Carmen Flores, et al.
Bone Marrow Transplantation|April 10, 2019
Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registryAnna Lübking, Arta Dreimane, Fredrik Sandin, et al.
Elife|November 6, 2024
Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy responseRebecca Warfvinge, Linda Geironson Ulfsson, Parashar Dhapola, et al.
Experimental Hematology|January 13, 2009
Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineageMarcus Järås, Petra Johnels, Helena Agerstam, et al.
Annals of Internal Medicine|June 14, 2016
Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort StudyTorsten Dahlén, Gustaf Edgren, Mats Lambe, et al.
Blood|June 18, 2010
Modeling the human 8p11-myeloproliferative syndrome in immunodeficient miceHelena Agerstam, Marcus Järås, Anna Andersson, et al.
Haematologica|December 30, 2017
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targetingNiklas Landberg, Sofia von Palffy, Maria Askmyr, et al.
Pageof 11